Steven Mah
Stock Analyst at TD Cowen
(2.22)
# 2,643
Out of 5,182 analysts
29
Total ratings
37.93%
Success rate
11.08%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $61.00 | -4.92% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $21.41 | +44.79% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $7.82 | +1,434.53% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $3.48 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $11.74 | +257.75% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $4.16 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $1.44 | +594.44% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $4.85 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $2.65 | +692.45% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $204.39 | -24.16% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $15.60 | +797.44% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.59 | +3,170.44% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $128.52 | +222.91% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $12.29 | +1,934.17% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $61.00
Upside: -4.92%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $21.41
Upside: +44.79%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $7.82
Upside: +1,434.53%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $3.48
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $11.74
Upside: +257.75%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.16
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $1.44
Upside: +594.44%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $4.85
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $2.65
Upside: +692.45%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $204.39
Upside: -24.16%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $15.60
Upside: +797.44%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.59
Upside: +3,170.44%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $128.52
Upside: +222.91%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $12.29
Upside: +1,934.17%